Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DTIL Stock Forecast 2025-2026
$5.02
Current Price
$120.84M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to DTIL Price Targets
+1,095.2%
To High Target of $60.00
+408.0%
To Median Target of $25.50
+278.5%
To Low Target of $19.00
DTIL Price Momentum
-7.7%
1 Week Change
-18.2%
1 Month Change
-14.3%
1 Year Change
+31.8%
Year-to-Date Change
-43.1%
From 52W High of $8.82
+39.1%
From 52W Low of $3.61
📊 TOP ANALYST CALLS
Did DTIL Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Precision BioSciences is one of their latest high-conviction picks.
Latest DTIL Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, DTIL has a bullish consensus with a median price target of $25.50 (ranging from $19.00 to $60.00). The overall analyst rating is N/A (N/A/10). Currently trading at $5.02, the median forecast implies a 408.0% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Patrick Trucchio at HC Wainwright & Co., projecting a 1,095.2% upside. Conversely, the most conservative target is provided by Debjit Chattopadhyay at Guggenheim, suggesting a 278.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DTIL Analyst Ratings
4
Buy
0
Hold
0
Sell
DTIL Price Target Range
Low
$19.00
Average
$25.50
High
$60.00
Current: $5.02
Latest DTIL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DTIL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 21, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
| Mar 28, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
| Mar 19, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
| Feb 19, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
| Jan 10, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
| Jan 10, 2025 | BMO Capital | Kostas Biliouris | Outperform | Upgrade | $34.00 |
| Aug 22, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
| May 30, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
| May 16, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
| Apr 30, 2024 | Guggenheim | Debjit Chattopadhyay | Buy | Initiates | $19.00 |
| Apr 17, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $60.00 |
| Mar 28, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $60.00 |
| Feb 14, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $3.00 |
| Sep 19, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $3.00 |
| Aug 17, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Maintains | $3.00 |
| Aug 7, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $N/A |
| Jul 28, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $5.00 |
| Jul 28, 2023 | BTIG | Thomas Shrader | Buy | Maintains | $2.00 |
| Jun 1, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $17.00 |
| Mar 15, 2023 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $17.00 |
Precision Biosciences Inc. (DTIL) Competitors
The following stocks are similar to Precision BioSciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
DTIL
Precision BioSciences
mkt cap
130.95M
Precision Biosciences Inc. (DTIL) Financial Data
Precision Biosciences Inc. has a market capitalization of $120.84M with a P/E ratio of 4.4x. The company generates $698,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -97.7% quarter-over-quarter, while maintaining an operating margin of -158,976.9% and return on equity of -205.2%.
Valuation Metrics
Market Cap
$120.84M
Enterprise Value
$51.34M
P/E Ratio
4.4x
PEG Ratio
-0.2x
Price/Sales
173.1x
Growth & Margins
Revenue Growth (YoY)
-97.7%
Gross Margin
N/A
Operating Margin
-158,976.9%
Net Margin
0.0%
EPS Growth
-97.7%
Financial Health
Cash/Price Ratio
+67.4%
Current Ratio
3.4x
Debt/Equity
175.1x
ROE
-205.2%
ROA
-45.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Precision Biosciences Inc. (DTIL) Business Model
About Precision Biosciences Inc.
What They Do
Develops gene editing technologies for health.
Business Model
The company utilizes its proprietary ARCUS genome editing platform to create therapeutic solutions for genetically-defined diseases, primarily generating revenue through the development and commercialization of its allogeneic CAR T cell therapies. These therapies are designed to provide off-the-shelf cancer treatment options, thereby addressing the limitations of traditional autologous therapies.
Additional Information
Founded in 2006 and headquartered in Durham, North Carolina, Precision Biosciences is dedicated to advancing personalized medicine and precision therapeutics. The firm plays a crucial role in the biopharmaceutical market by focusing on unmet medical needs in oncology and genetic disorders.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
102
CEO
Mr. Michael Amoroso
Country
United States
IPO Year
2015
Website
precisionbiosciences.comPrecision Biosciences Inc. (DTIL) Latest News & Analysis
Latest News
Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025
17 days ago
Quick Summary
Precision BioSciences (Nasdaq: DTIL) will present data from its Phase 1 ELIMINATE-B trial of PBGENE-HBV at the Hep-DART 2025 meeting on December 7-11, 2025, in Honolulu, Hawaii.
Why It Matters
Precision BioSciences' presentation on its Phase 1 trial for PBGENE-HBV signals progress in gene editing therapies, potentially impacting future valuations and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Precision BioSciences discussed advancements in its ARCUS platform and provided an update on the ELIMINATE-B clinical trial for chronic Hepatitis B during a conference call on November 11, 2025.
Why It Matters
Updates on Precision BioSciences' ARCUS platform and ELIMINATE-B trial can influence stock performance and investor sentiment, indicating potential breakthroughs in hepatitis B treatment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Precision BioSciences (Nasdaq: DTIL) will present data from its ELIMINATE-B Phase 1 study of PBGENE-HBV at the AASLD The Liver Meeting 2025. The therapy targets unmet needs in liver diseases.
Why It Matters
The announcement of a late-breaking presentation at a major conference highlights Precision BioSciences' advancements in gene editing, potentially boosting investor confidence and stock value.
Source: Business Wire
Market Sentiment:
Neutral
Precision BioSciences Announces $75 Million Offering of Common Stock, Pre-Funded Warrants and Warrants
26 days ago
Quick Summary
Precision BioSciences, Inc. plans to sell 10.8 million shares and warrants at $6.14 each in an underwritten offering to support its gene editing therapies.
Why It Matters
Precision BioSciences is raising capital through a stock offering, which can dilute existing shares but also fund development of its gene editing therapies, impacting future growth potential.
Source: Business Wire
Market Sentiment:
Neutral
Precision BioSciences Reports Third Quarter 2025 Financial Results and Provides Business Update
1 month ago
Quick Summary
Precision BioSciences reported progress in its gene editing pipeline and positive Phase 1 data for PBG in its Q3 2025 financial results.
Why It Matters
Positive Phase 1 data and progress in Precision BioSciences' gene editing pipeline may enhance investor confidence, potentially boosting stock value and attracting interest in biotech innovations.
Source: Business Wire
Market Sentiment:
Neutral
Precision BioSciences to Report Third Quarter 2025 Financial Results on November 3, 2025
1 month ago
Quick Summary
Precision BioSciences, Inc. (Nasdaq: DTIL) will release its Q3 2025 financial results and business update on November 3, 2025. The company focuses on in vivo gene editing therapies.
Why It Matters
The announcement of Precision BioSciences' Q3 2025 financial results and business update could influence investor sentiment and stock performance, particularly regarding its gene editing prospects.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About DTIL Stock
What is Precision Biosciences Inc.'s (DTIL) stock forecast for 2026?
Based on our analysis of 7 Wall Street analysts, Precision Biosciences Inc. (DTIL) has a median price target of $25.50. The highest price target is $60.00 and the lowest is $19.00.
Is DTIL stock a good investment in 2026?
According to current analyst ratings, DTIL has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.02. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DTIL stock?
Wall Street analysts predict DTIL stock could reach $25.50 in the next 12 months. This represents a 408.0% increase from the current price of $5.02. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Precision Biosciences Inc.'s business model?
The company utilizes its proprietary ARCUS genome editing platform to create therapeutic solutions for genetically-defined diseases, primarily generating revenue through the development and commercialization of its allogeneic CAR T cell therapies. These therapies are designed to provide off-the-shelf cancer treatment options, thereby addressing the limitations of traditional autologous therapies.
What is the highest forecasted price for DTIL Precision Biosciences Inc.?
The highest price target for DTIL is $60.00 from Patrick Trucchio at HC Wainwright & Co., which represents a 1,095.2% increase from the current price of $5.02.
What is the lowest forecasted price for DTIL Precision Biosciences Inc.?
The lowest price target for DTIL is $19.00 from Debjit Chattopadhyay at Guggenheim, which represents a 278.5% increase from the current price of $5.02.
What is the overall DTIL consensus from analysts for Precision Biosciences Inc.?
The overall analyst consensus for DTIL is bullish. Out of 7 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $25.50.
How accurate are DTIL stock price projections?
Stock price projections, including those for Precision Biosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 6, 2025 8:16 PM UTC